HK1252267A1 - 共有的新抗原 - Google Patents

共有的新抗原

Info

Publication number
HK1252267A1
HK1252267A1 HK18111576.9A HK18111576A HK1252267A1 HK 1252267 A1 HK1252267 A1 HK 1252267A1 HK 18111576 A HK18111576 A HK 18111576A HK 1252267 A1 HK1252267 A1 HK 1252267A1
Authority
HK
Hong Kong
Prior art keywords
shared neoantigens
neoantigens
shared
Prior art date
Application number
HK18111576.9A
Other languages
English (en)
Inventor
Edward F Fritsch
Nir Hacohen
Michael Steven Rooney
Sachet Ashok Shukla
Catherine J Wu
Pavan Bachireddy
Jing Sun
Original Assignee
Broad Inst Inc
Dana Farber Cancer Inst Inc
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc, Dana Farber Cancer Inst Inc, Massachusetts Gen Hospital filed Critical Broad Inst Inc
Publication of HK1252267A1 publication Critical patent/HK1252267A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
    • A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18111576.9A 2015-05-20 2018-09-07 共有的新抗原 HK1252267A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562179877P 2015-05-20 2015-05-20
US201662389377P 2016-02-23 2016-02-23

Publications (1)

Publication Number Publication Date
HK1252267A1 true HK1252267A1 (zh) 2019-05-24

Family

ID=56203902

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18110507.5A HK1251148A1 (zh) 2015-05-20 2018-08-15 共有的新抗原
HK18111576.9A HK1252267A1 (zh) 2015-05-20 2018-09-07 共有的新抗原

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18110507.5A HK1251148A1 (zh) 2015-05-20 2018-08-15 共有的新抗原

Country Status (21)

Country Link
US (2) US10835585B2 (zh)
EP (1) EP3297660A2 (zh)
JP (3) JP6913032B2 (zh)
KR (1) KR20180010229A (zh)
CN (2) CN116196401A (zh)
AU (2) AU2016264623B2 (zh)
BR (1) BR112017024797A2 (zh)
CA (1) CA2986235A1 (zh)
CL (2) CL2017002945A1 (zh)
CO (1) CO2017012835A2 (zh)
CR (3) CR20200476A (zh)
EC (1) ECSP17084137A (zh)
HK (2) HK1251148A1 (zh)
IL (3) IL294183B2 (zh)
MX (2) MX2017014700A (zh)
MY (1) MY190974A (zh)
PE (1) PE20180670A1 (zh)
PH (1) PH12017502321A1 (zh)
RU (2) RU2020132040A (zh)
TW (2) TWI806815B (zh)
WO (1) WO2016187508A2 (zh)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
KR101634833B1 (ko) 2008-10-22 2016-06-29 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
DK3699181T3 (da) 2014-11-16 2023-03-20 Array Biopharma Inc Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
BR112018008357A2 (pt) 2015-10-26 2018-11-27 Array Biopharma Inc mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
KR20180107102A (ko) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 신생항원 동정, 제조, 및 용도
WO2017124147A1 (en) * 2016-01-19 2017-07-27 The University Of Western Australia Novel biomolecule conjugates and uses therefor
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
US11154597B2 (en) 2016-03-24 2021-10-26 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
MA44524A (fr) * 2016-03-31 2019-02-06 Neon Therapeutics Inc Néoantigènes et leurs procédés d'utilisation
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
CA3056212A1 (en) * 2016-04-07 2017-10-12 Bostongene Corporation Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
WO2017190218A1 (en) * 2016-05-06 2017-11-09 University Health Network Liquid-biopsy signatures for prostate cancer
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
LT3458456T (lt) 2016-05-18 2021-02-25 Loxo Oncology, Inc. (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN109923121B (zh) * 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
WO2018098636A1 (zh) * 2016-11-29 2018-06-07 深圳华大基因研究院 多肽及其应用
AU2017367696A1 (en) * 2016-12-01 2019-06-20 Nant Holdings Ip, Llc Tumor antigenicity processing and presentation
PT3551753T (pt) 2016-12-09 2022-09-02 Harvard College Diagnósticos baseados num sistema efetor de crispr
JP7264482B2 (ja) 2016-12-23 2023-04-25 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
CN106868133A (zh) * 2017-02-24 2017-06-20 北京致成生物医学科技有限公司 一种监测肿瘤发生发展的产品及其应用
CA3056411A1 (en) 2017-03-15 2018-09-20 The Broad Institute, Inc. Crispr effector system based diagnostics for virus detection
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN108659114B (zh) * 2017-04-01 2022-10-21 中国科学院广州生物医药与健康研究院 识别pasd1抗原短肽的tcr
AU2018258119B2 (en) 2017-04-24 2021-04-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
TW202333779A (zh) 2017-05-08 2023-09-01 美商磨石生物公司 阿爾法病毒新抗原載體
US20200061112A1 (en) * 2017-05-10 2020-02-27 University Of Connecticut Dendritic Cells as a Novel Delivery System for Immunotherapy
CN111406068A (zh) * 2017-05-16 2020-07-10 约翰霍普金斯大学 MANAbody及使用方法
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
AU2018287169A1 (en) * 2017-06-22 2020-01-16 Neogap Therapeutics Ab T-cell expansion method and uses
NL2019156B1 (en) * 2017-06-30 2019-01-10 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Treatment of haematological malignancies
CA3067772A1 (en) * 2017-06-30 2019-01-03 Marieke GRIFFIOEN Treatment of haematological malignancies
CN107325171A (zh) * 2017-07-06 2017-11-07 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑7及其在制备治疗非小细胞肺癌的药物中的应用
CN107188955A (zh) * 2017-07-06 2017-09-22 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑3及其在制备治疗非小细胞肺癌的药物中的应用
CA3069047A1 (en) * 2017-07-12 2019-01-17 Nouscom Ag A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
US11918634B2 (en) * 2017-08-10 2024-03-05 Good T Cells, Inc. Method for activating T cells for cancer treatment
CN111315390A (zh) * 2017-09-05 2020-06-19 磨石肿瘤生物技术公司 用于t细胞疗法的新抗原鉴别
EP3683311A4 (en) * 2017-09-11 2021-06-02 National University Corporation Hokkaido University MEDICINE FOR THE TREATMENT OF CANCER
AU2018342246A1 (en) 2017-09-29 2020-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing mutated p53
CN111465989A (zh) 2017-10-10 2020-07-28 磨石肿瘤生物技术公司 使用热点进行的新抗原鉴别
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
DK3746568T3 (da) 2018-01-29 2023-12-18 Broad Inst Inc Crispr-effektorsystembaseret diagnostik
WO2019160099A1 (ja) * 2018-02-15 2019-08-22 大塚製薬株式会社 がん抗原ペプチド
US20210238690A1 (en) * 2018-04-26 2021-08-05 Intellexon Gmbh Hla-j and medical/diagnostic uses thereof
CN108588201B (zh) * 2018-05-11 2019-08-09 浙江省人民医院 一种结直肠癌西妥昔单抗耐药性痕量dna突变检测的方法及装置
EP3806961A4 (en) * 2018-05-11 2022-10-19 Memorial Sloan Kettering Cancer Center ANTI-PIK3CA MUTATION T-CELL RECEPTORS AND USES THEREOF
CN108588050B (zh) * 2018-05-14 2021-06-25 北京艾克伦医疗科技有限公司 Dna聚合酶以及核酸检测方法和试剂盒
JP2021525549A (ja) * 2018-05-25 2021-09-27 ザ ウィスター インスティテュート 腫瘍特異的ネオ抗原およびその使用方法
CN108728529B (zh) * 2018-06-06 2020-08-04 青岛泱深生物医药有限公司 Znf770基因在制备诊治子痫前期的产品中的应用
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN109142729B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-hmgb3自身抗体及其应用
JP7413286B2 (ja) * 2018-06-18 2024-01-15 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック Ｇａｇとそれらのエフェクター分子との相互作用を制御するリガンドおよびその使用
CN112584852A (zh) * 2018-06-19 2021-03-30 百欧恩泰美国公司 新抗原及其用途
CN112638404A (zh) * 2018-06-19 2021-04-09 百欧恩泰美国公司 新抗原及其用途
GB201810358D0 (en) * 2018-06-25 2018-08-08 Univ College Cardiff Consultants Ltd Cancer-specific t-cell receptors
US20210162032A1 (en) 2018-07-26 2021-06-03 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
EP3827263A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
US20210238244A1 (en) 2018-07-26 2021-08-05 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
WO2020022901A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
EP3827265A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US20220160870A1 (en) * 2018-08-28 2022-05-26 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
JP2021536247A (ja) * 2018-09-05 2021-12-27 バクシム アクチェンゲゼルシャフト 併用療法用ｄｎａワクチンを標的とするネオアンチゲン
CN109022585A (zh) * 2018-09-10 2018-12-18 路君 Pbld基因在制备肾透明细胞癌诊断和预测预后药物中的应用
TW202024133A (zh) * 2018-09-20 2020-07-01 日商第一三共股份有限公司 利用投予抗her3抗體-藥物結合物之her3突變癌之治療
CN109207431B (zh) * 2018-10-12 2021-10-15 武汉大学 一种抑制人癌基因STAT3的α亚型表达的方法
CN109486935A (zh) * 2018-10-18 2019-03-19 中国医学科学院北京协和医院 作为骨质疏松症诊治靶标的aknad1基因
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
CN111116754A (zh) * 2018-10-30 2020-05-08 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性tcr及其应用
WO2020092705A1 (en) * 2018-10-31 2020-05-07 University Of Virginia Patent Foundation Self-assembling peptides and hydrogels
CA3122378A1 (en) * 2018-11-01 2020-05-07 The Broad Institute, Inc. Identification of pde3 modulator responsive cancers
CN109504771A (zh) * 2018-11-19 2019-03-22 北京大学深圳医院（北京大学深圳临床医学院） Adcy2作为乳腺癌的分子标记物的应用
CN109438570B (zh) * 2018-11-28 2021-07-20 生命谷（海南）生物科技股份有限公司 肿瘤相关基因fgfr3突变短肽及其应用
CN109371026A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa_circACACB_035及其特异性扩增引物和应用
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN111363816B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于pax3和zic4基因的肺癌诊断试剂及试剂盒
CN109576362B (zh) * 2018-12-28 2020-09-04 青岛泱深生物医药有限公司 阿尔茨海默诊治用标志物fam170a
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
US20220127319A1 (en) * 2019-01-15 2022-04-28 Cornell University Recombinant mucins, and compositions and methods for using the same
CN112687325B (zh) * 2019-01-29 2024-01-26 杭州纽安津生物科技有限公司 针对靶向药物阿雷替尼、色瑞替尼、克唑替尼的多肽疫苗组合及其设计方法
US20220125839A1 (en) * 2019-02-13 2022-04-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination of t-cell therapy and targeted therapy for treating therapy-resistant melanoma with mutations in the braf gene
KR20210135008A (ko) 2019-02-20 2021-11-12 루비우스 테라퓨틱스, 아이엔씨. 적재가능한 항원 제시 폴리펩타이드를 포함하는 조작된 적혈구계 세포 및 이의 사용 방법
CN109735624A (zh) * 2019-03-14 2019-05-10 台州市立医院 基因标志物在甲状腺癌诊断中的应用
US20220153792A1 (en) * 2019-03-21 2022-05-19 Institute For Research In Biomedicine Peptide Inhibitors Targeting The CXCL12/HMGB1 Interaction And Uses Thereof
IL266728B (en) * 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
US11306122B2 (en) * 2019-06-14 2022-04-19 The United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor
JP2022537553A (ja) * 2019-06-20 2022-08-26 メモリアル スローン ケタリング キャンサー センター Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用
CN110358827A (zh) * 2019-07-09 2019-10-22 中国人民解放军第四军医大学 Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备
CN110358831B (zh) * 2019-07-11 2021-12-24 江苏医药职业学院 检测跨膜蛋白41a表达水平的试剂的应用和试剂盒
US20220289866A1 (en) * 2019-07-12 2022-09-15 The Regents Of The University Of California Chemically controlled monoclonal antibody target engagement
AU2020314851A1 (en) * 2019-07-16 2022-02-10 Washington University Anti-GRP78 antibodies and method of use thereof
WO2021022081A1 (en) * 2019-07-30 2021-02-04 Breakbio Corp. Method for treating solid tumors
EP4013494A1 (en) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
CN112402612B (zh) * 2019-08-21 2023-05-26 苏州蓝马医疗技术有限公司 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法
US20220396636A1 (en) * 2019-11-06 2022-12-15 Ohio State Innovation Foundation Targeting circular pcmtd1 in leukemias with p53 mutations and/or bcr/abl fusions
WO2021097365A2 (en) * 2019-11-15 2021-05-20 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
EP4081254A4 (en) 2019-12-23 2024-04-03 Univ California STABILIZATION OF MHC COMPLEXES
CN113117081A (zh) * 2019-12-30 2021-07-16 上海海洋大学 ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法
CN116134131A (zh) * 2019-12-31 2023-05-16 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
CN111116728B (zh) * 2020-01-13 2021-04-27 郑州大学 肿瘤特异性抗原ctl表位肽及其应用
EP4079758A4 (en) * 2020-01-21 2024-02-14 Shanghai Biotroy Biotechnique Co Ltd ANTI-SEMG2 ANTIBODIES AND ITS USE
EP4107176A4 (en) * 2020-02-20 2024-03-20 Gritstone Bio Inc ANTIGEN-BINDING PROTEINS TARGETING THE SHARED ANTIGEN KKLC-1
CN111303268B (zh) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗
CN113429473B (zh) * 2020-03-18 2022-11-04 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
CN113817740A (zh) * 2020-06-19 2021-12-21 中国科学院化学研究所 一种核酸适配体识别并结合ptprf及其相关功能的应用研究
CN111718405B (zh) * 2020-06-30 2022-09-13 青岛海兰深生物科技有限公司 一种检测抗胰腺癌天然抗体的组合物、试剂盒和方法
EP4176076A4 (en) * 2020-07-02 2024-05-01 Univ Johns Hopkins METHYLATED MARKERS FOR THE ACCURATE DETECTION OF PRIMARY CENTRAL NERVOUS SYSTEM AND SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
UY39467A (es) 2020-10-13 2022-04-29 Janssen Biotech Inc Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
AU2021381384A1 (en) * 2020-11-20 2023-06-22 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
EP4267605A2 (en) * 2020-12-23 2023-11-01 Janssen Biotech, Inc. Neoantigen peptide mimics
CN112666358A (zh) * 2021-01-14 2021-04-16 深圳裕康医学检验实验室 一种使用外周血检测抗原免疫原性的方法
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
WO2022179568A1 (en) * 2021-02-25 2022-09-01 Westlake Therapeutics (Hangzhou) Co., Limited Neoantigenic peptide and its use for treating braf gene mutation related diseases
WO2022193993A1 (zh) * 2021-03-16 2022-09-22 上海柏全生物科技有限公司 精液凝固蛋白的中和抗体及其表位和应用
CN114163510A (zh) * 2021-03-24 2022-03-11 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
CN113667001B (zh) * 2021-03-24 2023-03-31 深圳市新靶向生物科技有限公司 一种与肺癌驱动基因突变相关的抗原肽及其应用
CN114230655A (zh) * 2021-03-24 2022-03-25 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽组合及其应用
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
IL282814A (en) * 2021-04-29 2022-11-01 Yeda Res & Dev T-cell receptors against recurrent ras-derived neoantigens
JP2024517793A (ja) 2021-04-30 2024-04-23 ティゲン・ファーマ・ソシエテ・アノニム 単一容器リンパ球拡大
CN113527464A (zh) * 2021-07-19 2021-10-22 新景智源生物科技(苏州)有限公司 识别mboat2的tcr
CN117741161A (zh) * 2021-08-30 2024-03-22 河南中医药大学 Plekho2和npm3自身抗体在制备检测桥本甲状腺炎阴虚火旺证试剂盒中的应用
CN114085281A (zh) * 2021-10-15 2022-02-25 北京臻知医学科技有限责任公司 一种肿瘤抗原表位肽及其多聚体和应用
CN114085282A (zh) * 2021-10-15 2022-02-25 北京臻知医学科技有限责任公司 一种肿瘤新生抗原表位肽Pep6及其多聚体和应用
WO2023081655A1 (en) * 2021-11-02 2023-05-11 Fred Hutchinson Cancer Center T cell immunotherapy for hematologic malignancies having an sf3b1 mutation
KR20230068627A (ko) 2021-11-11 2023-05-18 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
KR20230068628A (ko) 2021-11-11 2023-05-18 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
CN114177274A (zh) * 2021-12-13 2022-03-15 中国医学科学院微循环研究所 Tdrd10蛋白及其编码基因在制备肿瘤治疗药物中的应用、及肿瘤治疗药物
WO2023114430A1 (en) * 2021-12-16 2023-06-22 The Johns Hopkins University Manabodies targeting p53 tumor antigens and methods of using
KR20230101284A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101287A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101285A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101283A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101286A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
WO2023150788A2 (en) * 2022-02-07 2023-08-10 Ubiquitx Beta-catenin protein degradation
CN114524872A (zh) * 2022-03-09 2022-05-24 广州诺诚生物技术研发有限公司 一种用于乳腺癌检测的单克隆抗体及其试剂盒
CN115327125A (zh) * 2022-07-14 2022-11-11 宁波大学 一种蛋白质inf2在制备肝癌诊断标志物中的应用
CN117586344A (zh) * 2022-08-12 2024-02-23 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
CN115651984B (zh) * 2022-10-20 2023-04-14 山东大学 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用
WO2024097864A1 (en) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes
EP4368189A1 (en) * 2022-11-09 2024-05-15 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms
CN116948004B (zh) * 2023-09-13 2023-11-21 成都朗谷生物科技股份有限公司 针对ctnnb1基因h36p突变的肿瘤新抗原多肽及其应用
CN117567591B (zh) * 2024-01-11 2024-04-26 中国人民解放军总医院 一种用于研究Tmem247蛋白的新型鼠源Tmem247抗体制备方法和应用

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4226859A (en) 1979-06-07 1980-10-07 Velsicol Chemical Corporation Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4743249A (en) 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4816540A (en) 1987-06-12 1989-03-28 Yasuhiko Onishi Cationic graft-copolymer
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
CA2005291C (en) 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
WO1991006309A1 (en) 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5198223A (en) 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
AU1588092A (en) 1991-02-22 1992-09-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Transmission blocking vaccine against malaria
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
HUP0000421A2 (hu) 1996-10-17 2000-06-28 Oxford Biomedica (Uk) Limited Retrovirális vektorok
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
AU9397098A (en) 1997-09-19 1999-04-12 Trustees Of The University Of Pennsylvania, The Methods and cell line useful for production of recombinant adeno-associated viruses
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
KR20010083890A (ko) 1998-10-05 2001-09-03 에드워드 에이. 맥더모트, 주니어 암 관련 항원 및 그의 용도
US6491907B1 (en) 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
PT1180159E (pt) 1999-05-28 2008-12-05 Targeted Genetics Corp Métodos e composições para abaixamento do nível de factor de necrose tumoral (tnf) nos distúrbios associados a tnf
EP1917970B1 (en) 1999-06-29 2011-06-15 Epimmune Inc. Hla binding peptides and their uses
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
JP2003523365A (ja) 2000-01-28 2003-08-05 スタテンズ セーラム インスティテュート Ｈｉｖ感染の診断及びコントロールのためのｈｉｖペプチド及びそれをエンコードする核酸
JP2004500095A (ja) 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
MXPA02008873A (es) 2000-03-14 2003-02-10 Anton Mayr Cepa alterada del virus de vaccinia ankara modificado (mva).
US6686184B1 (en) 2000-05-25 2004-02-03 President And Fellows Of Harvard College Patterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks
GB0024550D0 (zh) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US6923973B1 (en) 2001-02-22 2005-08-02 Board Of Regents, The University Of Texas System Peptide and DNA immunization against Coccidioides immitis infections
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
WO2003086459A1 (en) 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
PT1420822E (pt) 2002-04-19 2007-09-04 Bavarian Nordic As Vírus vacínia modificado ancara para a vacinação de neonatais
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
WO2003104427A2 (en) 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
JP2005529187A (ja) 2002-06-13 2005-09-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 同種抗原の特定方法、ならびに癌治療および移植へのその使用
JP2006507921A (ja) 2002-06-28 2006-03-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 流体分散のための方法および装置
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
WO2004026897A1 (ja) 2002-09-20 2004-04-01 Chugai Seiyaku Kabushiki Kaisha Ｗｔ１置換型ペプチド
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
DK1558643T3 (da) 2002-11-09 2009-09-07 Immunocore Ltd Cellereceptorpr sentation
WO2004058801A2 (en) 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP2266687A3 (en) 2003-04-10 2011-06-29 The President and Fellows of Harvard College Formation and control of fluidic species
US20080274129A1 (en) 2003-04-18 2008-11-06 Fikes John D Hla-A2 Tumor Associated Antigen Peptides and Compositions
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
SI1651265T1 (sl) 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
EP2662135A3 (en) 2003-08-27 2013-12-25 President and Fellows of Harvard College Method for mixing droplets in a microchannel
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
SG151261A1 (en) 2004-03-11 2009-04-30 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
US7084247B2 (en) 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
EP1765860B1 (en) 2004-05-19 2008-12-10 MediGene Ltd. High affinity ny-eso t cell receptor
CA2567349C (en) 2004-05-19 2012-11-27 Avidex Ltd Method of improving t cell receptors
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
ATE527281T1 (de) 2004-07-16 2011-10-15 Us Gov Health & Human Serv Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
EP1858332A4 (en) 2005-02-16 2011-06-22 Lentigen Corp LENTIVIRUS VECTORS AND ITS USE
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
CA2599683A1 (en) 2005-03-04 2006-09-14 President And Fellows Of Harvard College Method and apparatus for forming multiple emulsions
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
JP4976294B2 (ja) 2005-08-03 2012-07-18 株式会社医学生物学研究所 細胞傷害性ｔ細胞エピトープペプチド及びその用途
SI3611266T1 (sl) 2005-08-23 2023-02-28 The Trustees Of The University Of Pennsylvania Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo
US20070112754A1 (en) 2005-11-15 2007-05-17 Honeywell International Inc. Method and apparatus for identifying data of interest in a database
EP3913375A1 (en) 2006-01-11 2021-11-24 Bio-Rad Laboratories, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
JP2009524825A (ja) 2006-01-27 2009-07-02 プレジデント アンド フェロウズ オブ ハーバード カレッジ 流体ドロップレットの合体
US8793895B2 (en) 2006-02-10 2014-08-05 Praxair Technology, Inc. Lyophilization system and method
US20090186042A1 (en) 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP2481815B1 (en) 2006-05-11 2016-01-27 Raindance Technologies, Inc. Microfluidic devices
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2009538607A (ja) 2006-06-02 2009-11-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 患者が免疫療法に対する応答者であるかどうかを同定する方法
WO2008011344A2 (en) 2006-07-17 2008-01-24 Nationwide Children's Hospital Inc. Disruption of programmed death-1 (pd-1) ligands to adjuvant adeno-associated virus vector vaccines
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
US8349167B2 (en) 2006-12-14 2013-01-08 Life Technologies Corporation Methods and apparatus for detecting molecular interactions using FET arrays
EP2127671B1 (en) 2007-02-07 2016-09-14 Nec Corporation Therapeutic agent for cancer
WO2008109075A2 (en) 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
DK2829282T3 (en) 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
ES2406077T3 (es) 2007-05-31 2013-06-05 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vacuna de péptido p53
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN102264755A (zh) 2007-08-08 2011-11-30 得克萨斯大学体系董事会 靶向vegfr-1/nrp-1的肽
WO2009043520A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
ES2824154T3 (es) 2007-10-25 2021-05-11 Toray Industries Inductor de la respuesta inmunitaria
EP2238265A4 (en) 2007-12-28 2012-01-18 Wayne John Cancer Inst USE OF THE METHYLATION STATE OF MINT-LOCI AND TUMOR ASSOCIATED GENES AS A MARKER FOR MELANOMA AND MAMMARIAN CARCINOMA
NZ587060A (en) 2007-12-31 2012-09-28 Nanocor Therapeutics Inc Rna interference for the treatment of heart failure
WO2009102909A2 (en) 2008-02-15 2009-08-20 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US10000568B2 (en) 2008-04-10 2018-06-19 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR in cancer
CA2738031C (en) 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
KR20110069092A (ko) 2008-10-17 2011-06-22 제넨테크, 인크. 치료 방법
US20100137143A1 (en) 2008-10-22 2010-06-03 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
CA2756238A1 (en) 2009-04-02 2010-10-07 Vaxon Biotech Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
EP2509583B1 (en) 2009-12-10 2019-05-15 Merck Patent GmbH Pharmaceutical composition comprising oligopeptides, preferably cilengitide
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CN102946907A (zh) 2010-05-28 2013-02-27 牛津生物医学（英国）有限公司 慢病毒载体向脑的递送
SG186109A1 (en) 2010-06-02 2013-01-30 Abraxis Bioscience Llc Methods of treating bladder cancer
WO2012027379A2 (en) 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
EP3305798A1 (en) 2010-12-09 2018-04-11 The Trustees of The University of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012206487A1 (en) 2011-01-14 2013-07-18 Genefirst Limited Methods, compositions, and kits for determining the presence/absence of a variant nucleic acid sequence
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US20120295960A1 (en) 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
CA2836494C (en) 2011-05-24 2023-01-03 Biontech Ag Individualized vaccines for cancer
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2013026027A1 (en) 2011-08-18 2013-02-21 Nestec S.A. Compositions and methods for detecting allelic variants
WO2013036201A1 (en) * 2011-09-06 2013-03-14 Agency For Science, Technology And Research Polypeptide vaccine
ES2689512T3 (es) 2011-09-15 2018-11-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptores de células T que reconocen MAGE restringido por HLA-A1 o a HLA-Cw7
US20140255363A1 (en) 2011-09-16 2014-09-11 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
US20140364439A1 (en) 2011-12-07 2014-12-11 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20130210014A1 (en) 2012-02-10 2013-08-15 Jeff Sharman Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients
EP2814985A4 (en) 2012-02-15 2016-03-30 Janssen Diagnostics Llc EXTREMELY SENSITIVE METHOD OF DETECTING LOW FREQUENCY MUTATIONS
EP2823824A4 (en) 2012-03-09 2015-09-16 Oncotherapy Science Inc PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE
CA2872471C (en) 2012-05-03 2022-11-22 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
EP3563865A3 (en) 2012-05-04 2019-12-04 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
ES2962571T3 (es) 2012-05-25 2024-03-19 Cellectis Métodos para modificar células T alogénicas y resistentes a la inmunosupresión para inmunoterapia
WO2013188831A1 (en) 2012-06-15 2013-12-19 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
PL2872646T3 (pl) 2012-07-12 2018-03-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów
CN104662171B (zh) 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
CA2878856A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating car t cells
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
CA2883569A1 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP2898096B1 (en) 2012-09-21 2024-02-14 The Broad Institute, Inc. Methods for labeling of rnas
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
WO2014056986A1 (en) 2012-10-11 2014-04-17 Universitat De Barcelona Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll)
EP2925447B1 (en) 2012-11-30 2020-04-08 The Broad Institute, Inc. High-throughput dynamic reagent delivery system
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP3346016B1 (en) 2013-02-07 2019-10-02 Rutgers, the State University of New Jersey Highly selective nucleic acid amplification primers
KR20210108497A (ko) 2013-02-26 2021-09-02 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
US9844569B2 (en) 2013-03-01 2017-12-19 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
CN105163744A (zh) 2013-03-01 2015-12-16 美国卫生和人力服务部 从肿瘤中产生肿瘤反应性t细胞的富集群的方法
US10176294B2 (en) 2013-03-15 2019-01-08 The Broad Institute, Inc. Accurate typing of HLA through exome sequencing
KR20230145545A (ko) 2013-04-07 2023-10-17 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
WO2014172606A1 (en) 2013-04-19 2014-10-23 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
EP2997133B1 (en) 2013-05-13 2023-08-23 Cellectis Methods for engineering highly active t cell for immunotherapy
ES2645393T3 (es) 2013-05-29 2017-12-05 Cellectis Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
EP3004877A4 (en) * 2013-06-06 2017-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US20160310584A1 (en) 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
JP6840072B2 (ja) 2014-06-05 2021-03-10 アイム・セラピューティクス・べー・フェー Ｔ細胞認識を決定するための手段及び方法
PT3198026T (pt) 2014-08-07 2020-01-16 Pharmassist Ltd Método de determinação do estado mutacional de pik3ca numa amostra
US20170298441A1 (en) 2014-09-22 2017-10-19 Dana-Farber Cancer Institute, Inc Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
CA2987730C (en) * 2015-04-08 2020-02-18 Nantomics, Llc Cancer neoepitopes
CN108513593A (zh) * 2015-04-23 2018-09-07 南托米克斯有限责任公司 癌症新表位
US20180127803A1 (en) 2015-05-10 2018-05-10 Quandx Inc. Ultra sensitive probes for detection of nucleic acid
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
MA44524A (fr) 2016-03-31 2019-02-06 Neon Therapeutics Inc Néoantigènes et leurs procédés d'utilisation
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide

Also Published As

Publication number Publication date
RU2020132040A (ru) 2020-10-12
RU2733754C2 (ru) 2020-10-06
CL2017002945A1 (es) 2018-04-27
IL294183A (en) 2022-08-01
AU2016264623A1 (en) 2017-12-07
AU2016264623B2 (en) 2022-06-30
MX2017014700A (es) 2018-08-15
RU2017144467A3 (zh) 2019-11-20
IL302102A (en) 2023-06-01
CA2986235A1 (en) 2016-11-24
CR20200476A (es) 2020-12-02
RU2017144467A (ru) 2019-06-20
CN108025048A (zh) 2018-05-11
MX2023005122A (es) 2023-07-13
EP3297660A2 (en) 2018-03-28
US20200368337A1 (en) 2020-11-26
HK1251148A1 (zh) 2019-01-25
WO2016187508A3 (en) 2017-01-12
CN116196401A (zh) 2023-06-02
JP6913032B2 (ja) 2021-08-04
PE20180670A1 (es) 2018-04-19
BR112017024797A2 (pt) 2018-08-07
CR20170584A (es) 2018-03-20
TW202346325A (zh) 2023-12-01
WO2016187508A2 (en) 2016-11-24
IL294183B2 (en) 2023-10-01
JP2018522822A (ja) 2018-08-16
JP2021176866A (ja) 2021-11-11
TWI806815B (zh) 2023-07-01
IL255769B2 (en) 2023-09-01
JP7282834B2 (ja) 2023-05-29
IL255769A (en) 2018-01-31
AU2022241521A1 (en) 2022-12-01
IL294183B1 (en) 2023-06-01
CO2017012835A2 (es) 2018-05-10
TW201808327A (zh) 2018-03-16
JP2023103405A (ja) 2023-07-26
ECSP17084137A (es) 2018-05-31
PH12017502321A1 (en) 2018-06-25
IL255769B1 (en) 2023-05-01
US20180153975A1 (en) 2018-06-07
CN108025048B (zh) 2022-10-25
MY190974A (en) 2022-05-25
US10835585B2 (en) 2020-11-17
KR20180010229A (ko) 2018-01-30
CR20230191A (es) 2023-07-06
CL2023002421A1 (es) 2024-02-09

Similar Documents

Publication Publication Date Title
HK1252267A1 (zh) 共有的新抗原
SG11201705976UA (en) Cryoneedle
AU361999S (en) Ballustrade
PL3124119T3 (pl) Odkiełkownica
GB201511225D0 (en) Novel structure
PL3257657T3 (pl) Struktura zapobiegająca wyciekaniu
GB2541867B (en) Polytunnel arrangement
GB2536816B (en) Combining arrangement
GB201516249D0 (en) Liqui-glove
GB2544388B (en) Polytunnel Arrangement
GB2540412B (en) Polytunnel arrangement
GB2545956B (en) Vibro-polishing arrangement
RS63420B1 (sr) Peg-vezivo
GB201617732D0 (en) Corbel-Pro
GB201614041D0 (en) Not present
AU5511P (en) PTK647 Epichloe coenophiala
AU366552S (en) Nutblock
GB201520298D0 (en) Thingy
ZA201507180B (en) An overall
AU367131S (en) USB-charger
GB201517693D0 (en) Buggys
GB201516942D0 (en) Flightpal
GB201515248D0 (en) Polytunnel structure
AU365008S (en) Playsuit
GB201510814D0 (en) Van2Campervan